Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma A Canadian high risk endometrial cancer consortium (CHREC) study
Material type:
TextPublisher number: Phone: +255 28 298 3384 Fax: +255 28 298 3386 Email: vc@bugando.ac.tz Website: www.bugando.ac.tz Language: English Series: ; Gynecologic Oncology Volume 141 Issue 3 Publication details: Mwanza, Tanzania: Academic Press & Catholic University of Health and Allied Sciences [CUHAS – Bugando] 2016/6/1 Description: Pages 559-563Summary: Abstract
Objective
To assess the association of hormone receptor expression with outcome in high-grade endometrial carcinomas.
Methods
This study included three sites participating in the Canadian High Risk Endometrial Cancer (CHREC) consortium. Sections from tissue microarrays containing cases with a diagnosis of endometrioid grade 3 (EC3) and endometrial serous carcinoma (ESC) were assessed for estrogen (ER) and progesterone receptor (PR) expression by immunohistochemistry. Expression was considered present if > 1% of tumor cell nuclei were labeled. Associations with overall survival were assessed.
Results
ER expression was present in 168/216 (78%) of EC3 and 124/192 (65%) of ESC. PR expression was present in 148/212 (70%) of EC3 and 83/196 (42%) of ESC.
PR expression was significantly associated with favorable overall survival in EC3 and ESC (log rank, p = 0.018 and p = 0.0024) but ER expression was not. PR expression was significantly associated with favorable overall survival in EC3 independent of age, stage, center and lymph-vascular invasion (hazard ratio = 0.457, 95% CI 0.257–0.811, p = 0.0075) as well as in stage I and II ESC (hazard ratio = 0.266, 95% CI 0.094–0.750, p = 0.0123).
Conclusion
Our data provide support for the assessment of the PR expression status in EC3 and ESC. Future work will be required to determine how PR expression may be incorporated into management of patients with EC3 and ESC.
| Item type | Current library | Collection | Status | Barcode | |
|---|---|---|---|---|---|
| RESEARCH ARTICLES | MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | NFIC | -1 | RA0342 |
Abstract
Objective
To assess the association of hormone receptor expression with outcome in high-grade endometrial carcinomas.
Methods
This study included three sites participating in the Canadian High Risk Endometrial Cancer (CHREC) consortium. Sections from tissue microarrays containing cases with a diagnosis of endometrioid grade 3 (EC3) and endometrial serous carcinoma (ESC) were assessed for estrogen (ER) and progesterone receptor (PR) expression by immunohistochemistry. Expression was considered present if > 1% of tumor cell nuclei were labeled. Associations with overall survival were assessed.
Results
ER expression was present in 168/216 (78%) of EC3 and 124/192 (65%) of ESC. PR expression was present in 148/212 (70%) of EC3 and 83/196 (42%) of ESC.
PR expression was significantly associated with favorable overall survival in EC3 and ESC (log rank, p = 0.018 and p = 0.0024) but ER expression was not. PR expression was significantly associated with favorable overall survival in EC3 independent of age, stage, center and lymph-vascular invasion (hazard ratio = 0.457, 95% CI 0.257–0.811, p = 0.0075) as well as in stage I and II ESC (hazard ratio = 0.266, 95% CI 0.094–0.750, p = 0.0123).
Conclusion
Our data provide support for the assessment of the PR expression status in EC3 and ESC. Future work will be required to determine how PR expression may be incorporated into management of patients with EC3 and ESC.
There are no comments on this title.
Click on an image to view it in the image viewer